Payment overview · 2025
General Payments
$879.36
44 reported records · 17 companies
Healthcare provider profile · identity verified
Norberto Alvarez, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAREDO, TX · NPI 1730383324
Verified facts
What the public records show
CMS Open Payments records show Norberto Alvarez, MD received $879.36 in general payments during 2025 across 44 reported records.
Corcept Therapeutics accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $218.96 | 24.9% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.41 | 11.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $87.04 | 9.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.58 | 8.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.49 | 7.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.24 | 7.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.07 | 5.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.16 | 5.0% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $25.96 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.07 | 2.6% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.79 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.53 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.52 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.40 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.24 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.44 | 1.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.46 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.09 | 43 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $218.96 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $99.41 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $87.04 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.07 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 237 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 310 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
195 | 92 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
106 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
237 | 84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
144 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
236 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
237 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
310 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1392 | 482 |
| Levothyroxine Sodium | Levothyroxine Sodium | 577 | 194 |
| Losartan Potassium | Losartan Potassium | 566 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 213 |
| Metformin Hcl | Metformin Hcl | 550 | 208 |
| Omeprazole | Omeprazole | 536 | 245 |
| Gabapentin | Gabapentin | 493 | 208 |
| Pioglitazone Hcl | Pioglitazone Hcl | 460 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 181 |
| Tramadol Hcl | Tramadol Hcl | 450 | 130 |
| Alprazolam | Alprazolam | 444 | 89 |
| Lisinopril | Lisinopril | 398 | 138 |
| Fluticasone Propionate | Fluticasone Propionate | 383 | 190 |
| Clopidogrel | Clopidogrel Bisulfate | 348 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 134 |
| Tizanidine Hcl | Tizanidine Hcl | 319 | 184 |
| Ozempic | Semaglutide | 310 | 77 |
| Glipizide | Glipizide | 291 | 95 |
| Furosemide | Furosemide | 288 | 117 |
| Meloxicam | Meloxicam | 274 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 108 |
| Enalapril Maleate | Enalapril Maleate | 267 | 74 |
| Simvastatin | Simvastatin | 244 | 85 |
| Jardiance | Empagliflozin | 237 | 84 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 236 | 54 |
| Januvia | Sitagliptin Phosphate | 232 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 80 |
| Clonazepam | Clonazepam | 224 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 222 | 72 |
| Donepezil Hcl | Donepezil Hcl | 213 | 65 |
| Temazepam | Temazepam | 201 | 60 |
| Famotidine | Famotidine | 199 | 82 |
| Linzess | Linaclotide | 195 | 92 |
| Ibuprofen | Ibuprofen | 191 | 104 |
| Finasteride | Finasteride | 185 | 69 |
| Montelukast Sodium | Montelukast Sodium | 184 | 70 |
| Alendronate Sodium | Alendronate Sodium | 180 | 71 |
| Carvedilol | Carvedilol | 180 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 69 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 154 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 50 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 148 | 85 |
| Hydralazine Hcl | Hydralazine Hcl | 147 | 49 |
| Pregabalin | Pregabalin | 146 | 48 |
| Tradjenta | Linagliptin | 145 | 49 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 144 | 61 |
| Synjardy | Empagliflozin/Metformin Hcl | 144 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 62 |
| Ezetimibe | Ezetimibe | 142 | 61 |
| Clonidine Hcl | Clonidine Hcl | 138 | 42 |
| Meclizine Hcl | Meclizine Hcl | 138 | 79 |
| Eliquis | Apixaban | 135 | 27 |
| Sertraline Hcl | Sertraline Hcl | 123 | 38 |
| Trazodone Hcl | Trazodone Hcl | 123 | 42 |
| Methylprednisolone | Methylprednisolone | 122 | 109 |
| Farxiga | Dapagliflozin Propanediol | 121 | 52 |
| Megestrol Acetate | Megestrol Acetate | 121 | 51 |
| Celecoxib | Celecoxib | 118 | 68 |
| Azelastine Hcl | Azelastine Hcl | 117 | 63 |
| Myrbetriq | Mirabegron | 117 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 28 |
| Nifedipine Er | Nifedipine | 115 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 106 | 41 |
| Kerendia | Finerenone | 106 | 39 |
| Gemfibrozil | Gemfibrozil | 105 | 39 |
| Potassium Chloride | Potassium Chloride | 100 | 25 |
| Entresto | Sacubitril/Valsartan | 97 | 19 |
| Lactulose | Lactulose | 97 | 39 |
| Sucralfate | Sucralfate | 94 | 32 |
| Allopurinol | Allopurinol | 92 | 35 |
| Lorazepam | Lorazepam | 91 | 12 |
| Glimepiride | Glimepiride | 90 | 34 |
| Cefdinir | Cefdinir | 88 | 73 |
| Acarbose | Acarbose | 87 | 25 |
| Levetiracetam | Levetiracetam | 87 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 84 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 71 |
| Cilostazol | Cilostazol | 79 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 30 |
| Metformin Hcl Er | Metformin Hcl | 74 | 34 |
| Diclofenac Potassium | Diclofenac Potassium | 72 | 43 |
| Prednisone | Prednisone | 70 | 61 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 20 |
| Fenofibrate | Fenofibrate | 67 | 32 |
| Buspirone Hcl | Buspirone Hcl | 65 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 62 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | suppressed |
| Chlorthalidone | Chlorthalidone | 60 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 22 |
| Terbinafine Hcl | Terbinafine Hcl | 58 | 39 |
| Eszopiclone | Eszopiclone | 57 | 23 |
| Labetalol Hcl | Labetalol Hcl | 57 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 54 |
| Azithromycin | Azithromycin | 56 | 53 |
| Glipizide Er | Glipizide | 56 | 20 |
| Xarelto | Rivaroxaban | 56 | 18 |
| Verapamil Er | Verapamil Hcl | 55 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 54 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 38 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Mirtazapine | Mirtazapine | 51 | 14 |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Rybelsus | Semaglutide | 50 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | 16 |
| Clonidine | Clonidine | 48 | 18 |
| Betamethasone Valerate | Betamethasone Valerate | 47 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 20 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 36 |
| Topiramate | Topiramate | 45 | 26 |
| Trulicity | Dulaglutide | 44 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 43 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 29 |
| Ammonium Lactate | Ammonium Lactate | 41 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 13 |
| Midodrine Hcl | Midodrine Hcl | 40 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 24 |
| Ramipril | Ramipril | 40 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Risperidone | Risperidone | 39 | suppressed |
| Belsomra | Suvorexant | 38 | 16 |
| Fluconazole | Fluconazole | 37 | 26 |
| Naproxen | Naproxen | 37 | 18 |
| Telmisartan | Telmisartan | 37 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 16 |
| Hydrocortisone | Hydrocortisone | 35 | 19 |
| Primidone | Primidone | 35 | 13 |
| Levemir Flexpen | Insulin Detemir | 33 | 14 |
| Benazepril Hcl | Benazepril Hcl | 32 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 15 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 15 |
| Spironolactone | Spironolactone | 31 | 16 |
| Levofloxacin | Levofloxacin | 30 | 28 |
| Digoxin | Digoxin | 29 | 12 |
| Valsartan | Valsartan | 29 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | 11 |
| Captopril | Captopril | 28 | 11 |
| Baclofen | Baclofen | 27 | suppressed |
| Constulose | Lactulose | 27 | 16 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | 19 |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Enulose | Lactulose | 25 | 13 |
| Novolin N | Insulin Nph Human Isophane | 25 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Zonisamide | Zonisamide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 22 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 14 |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 15 |
| Nystatin | Nystatin | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | 11 |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | 11 |
| Mupirocin | Mupirocin | 12 | 11 |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Permethrin | Permethrin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $879.36 · 44 records | Corcept Therapeutics | AREXVY, Auvelity, CAPVAXIVE, CeQur Simplicity, GEMTESA, JARDIANCE, Kerendia, Korlym, LYBALVI, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, Quviviq, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VRAYLAR, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error